BRAFV600E mutation analysis in patients with metastatic colorectal cancer (mCRC) in daily clinical practice: Correlations with clinical characteristics, and its impact on patients' outcome

PLoS ONE

Volumn 8, Issue 12, 2013, Pages

  Saridaki, Zacharenia ^a,b   Tzardi, Maria ^b   Sfakianaki, Maria ^a   Papadaki, Chara ^a   Voutsina, Alexandra ^a   Kalykaki, Aristea ^a   Messaritakis, Ippokratis ^a   Mpananis, Kyriakos ^a   Mavroudis, Dimitris ^a,b   Stathopoulos, Efstathios ^b   Georgoulias, Vassilis ^a,b   Souglakos, John ^a,b  

^a UNIVERSITY OF CRETE   (Greece)

^b UNIVERSITY HOSPITAL OF HERAKLION   (Greece)

Author keywords

[No Author keywords available]

Indexed keywords

BEVACIZUMAB; CETUXIMAB; EPIDERMAL GROWTH FACTOR RECEPTOR ANTIBODY; IRINOTECAN; OXALIPLATIN; PANITUMUMAB;

ADULT; AGED; ARTICLE; BRAFV600E GENE; CANCER CHEMOTHERAPY; CANCER COMBINATION CHEMOTHERAPY; CANCER GRADING; CANCER SURVIVAL; CLINICAL EVALUATION; CONTROLLED STUDY; DRUG EFFICACY; DRUG RESPONSE; FEMALE; GENE FREQUENCY; GENE MUTATION; HUMAN; HUMAN CELL; HUMAN TISSUE; MAJOR CLINICAL STUDY; MALE; METASTATIC COLORECTAL CANCER; MUTATIONAL ANALYSIS; ONCOGENE; ONCOGENE K RAS; OVERALL SURVIVAL; PROGRESSION FREE SURVIVAL; SALVAGE THERAPY; TREATMENT DURATION;

AGE FACTORS; AGED; COLORECTAL NEOPLASMS; DISEASE-FREE SURVIVAL; FEMALE; HUMANS; MALE; MIDDLE AGED; MULTIVARIATE ANALYSIS; MUTATION, MISSENSE; PROGNOSIS; PROSPECTIVE STUDIES; PROTO-ONCOGENE PROTEINS; PROTO-ONCOGENE PROTEINS B-RAF; RAS PROTEINS;

EID: 84893164570     PISSN: None     EISSN: 19326203     Source Type: Journal    
DOI: 10.1371/journal.pone.0084604     Document Type: Article

References (24)

1. Davies H, Bignell GR, Cox C, Stephens P, Edkins S et al. (2002) Mutations of the BRAF gene in human cancer. Nature 417: 949-954. doi:10.1038/nature00766. PubMed: 12068308.
2. http: and www.sanger.ac.uk/genetics/CGP/cosmic/. COSMIC database. 13 A.D. Ref type: internet communication
3. Di Nicolantonio F, Martini M, Molinari F, Sartore-Bianchi A, Arena S et al. (2008) Wild-type BRAF is required for response to panitumumab or cetuximab in metastatic colorectal cancer. J Clin Oncol 26: 5705-5712. doi:10.1200/JCO.2008.18.0786. PubMed: 19001320.
4. French AJ, Sargent DJ, Burgart LJ, Foster NR, Kabat BF et al. (2008) Prognostic significance of defective mismatch repair and BRAF V600E in patients with colon cancer. Clin Cancer Res 14: 3408-3415. doi: 10.1158/1078-0432.CCR-07- 1489. PubMed: 18519771.
5. Ogino S, Nosho K, Kirkner GJ, Kawasaki T, Meyerhardt JA et al. (2009) CpG island methylator phenotype, microsatellite instability, BRAF mutation and clinical outcome in colon cancer. Gut 58: 90-96. doi: 10.1136/gut.2008.155473. PubMed: 18832519.
6. Samowitz WS, Sweeney C, Herrick J, Albertsen H, Levin TR et al. (2005) Poor survival associated with the BRAF V600E mutation in microsatellite-stable colon cancers. Cancer Res 65: 6063-6069. doi: 10.1158/0008-5472.CAN-05-0404. PubMed: 16024606.
7. Saridaki Z, Tzardi M, Papadaki C, Sfakianaki M, Pega F, et al. (2011) Impact of KRAS, BRAF, PIK3CA mutations, PTEN, AREG, EREG expression and skin rash in >/= 2 line cetuximab-based therapy of colorectal cancer patients. PLOS ONE 6: e15980.
8. Souglakos J, Philips J, Wang R, Marwah S, Silver M et al. (2009) Prognostic and predictive value of common mutations for treatment response and survival in patients with metastatic colorectal cancer. Br J Cancer 101: 465-472. doi:10.1038/sj.bjc.6605164. PubMed: 19603024.
9. Oliveira C, Pinto M, Duval A, Brennetot C, Domingo E et al. (2003) BRAF mutations characterize colon but not gastric cancer with mismatch repair deficiency. Oncogene 22: 9192-9196. doi:10.1038/sj.onc.1207061. PubMed: 14668801.
10. Rajagopalan H, Bardelli A, Lengauer C, Kinzler KW, Vogelstein B et al. (2002) Tumorigenesis: RAF/RAS oncogenes and mismatch-repair status. Nature 418: 934. doi:10.1038/418934a. PubMed: 12198537.
11. Saridaki Z, Papadatos-Pastos D, Tzardi M, Mavroudis D, Bairaktari E et al. (2010) BRAF mutations, microsatellite instability status and cyclin D1 expression predict metastatic colorectal patients' outcome. Br J Cancer 102: 1762-1768. doi:10.1038/sj.bjc.6605694. PubMed: 20485284.
12. Domingo E, Laiho P, Ollikainen M, Pinto M, Wang L et al. (2004) BRAF screening as a low-cost effective strategy for simplifying HNPCC genetic testing. J Med Genet 41: 664-668. doi:10.1136/jmg.2004.020651. PubMed: 15342696.
13. Wang L, Cunningham JM, Winters JL, Guenther JC, French AJ et al. (2003) BRAF mutations in colon cancer are not likely attributable to defective DNA mismatch repair. Cancer Res 63: 5209-5212. PubMed: 14500346.
14. Roth AD, Tejpar S, Delorenzi M, Yan P, Fiocca R et al. (2010) Prognostic role of KRAS and BRAF in stage II and III resected colon cancer: results of the translational study on the PETACC-3, EORTC 40993, SAKK 60-00 trial. J Clin Oncol 28: 466-474. doi:10.1200/JCO.2009.23.3452. PubMed: 20008640.
15. Popovici V, Budinska E, Tejpar S, Weinrich S, Estrella H et al. (2012) Identification of a poor-prognosis BRAF-mutant-like population of patients with colon cancer. J Clin Oncol 30: 1288-1295. doi:10.1200/JCO.2011.39.5814. PubMed: 22393095.
16. De Roock W, Claes B, Bernasconi D, De Schutter J, Biesmans B et al. (2010) Effects of KRAS, BRAF, NRAS, and PIK3CA mutations on the efficacy of cetuximab plus chemotherapy in chemotherapy-refractory metastatic colorectal cancer: a retrospective consortium analysis. Lancet Oncol 11: 753-762. doi:10.1016/S1470-2045(10)70130-3. PubMed: 20619739.
17. Loupakis F, Ruzzo A, Cremolini C, Vincenzi B, Salvatore L et al. (2009) KRAS codon 61, 146 and BRAF mutations predict resistance to cetuximab plus irinotecan in KRAS codon 12 and 13 wild-type metastatic colorectal cancer. Br J Cancer 101: 715-721. doi:10.1038/sj.bjc.6605177. PubMed: 19603018.
18. Tol J, Nagtegaal ID, Punt CJ (2009) BRAF mutation in metastatic colorectal cancer. N Engl J Med 361: 98-99. doi:10.1056/NEJMc0904160. PubMed: 19571295.
19. Van Cutsem E, Köhne CH, Láng I, Folprecht G, Nowacki MP et al. (2011) Cetuximab plus irinotecan, fluorouracil, and leucovorin as first-line treatment for metastatic colorectal cancer: updated analysis of overall survival according to tumor KRAS and BRAF mutation status. J Clin Oncol 29: 2011-2019. doi:10.1200/JCO.2010.33.5091. PubMed: 21502544.
20. Benlloch S, Payá A, Alenda C, Bessa X, Andreu M et al. (2006) Detection of BRAF V600E mutation in colorectal cancer: comparison of automatic sequencing and real-time chemistry methodology. J Mol Diagn 8: 540-543. doi:10.2353/jmoldx.2006.060070. PubMed: 17065421.
21. Pentheroudakis G, Kotoula V, De Roock W, Kouvatseas G, Papakostas P et al. (2013) Biomarkers of benefit from cetuximab-based therapy in metastatic colorectal cancer: interaction of EGFR ligand expression with RAS/RAF, PIK3CA genotypes. BMC Cancer 13: 49. doi: 10.1186/1471-2407-13-49. PubMed: 23374602.
22. Oliner KS, Douillard J-Y, Siena S, Tabernero J, Burkes R et al. (2013) Analysis of KRAS/NRAS and BRAF mutations in the phase III PRIME study of panitumumab (pmab) plus FOLFOX versus FOLFOX as firstline treatment (tx) for metastatic colorectal cancer (mCRC). J Clin Oncol 31 suppl, Abstr: 3511.
23. Solit DB, Garraway LA, Pratilas CA, Sawai A, Getz G et al. (2006) BRAF mutation predicts sensitivity to MEK inhibition. Nature 439: 358-362. doi:10.1038/nature04304. PubMed: 16273091.
24. Schmoll HJ, Van Cutsem E, Stein A, Valentini V, Glimelius B et al. (2012) ESMO Consensus Guidelines for management of patients with colon and rectal cancer. a personalized approach to clinical decision making. Ann Oncol 23: 2479-2516. doi:10.1093/annonc/mds236. PubMed: 23012255.